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Abstract
Objective: To evaluate the success rate of therapeutic administration of a single calculated 131I activity for
eliminating hyperthyroidism due to Graves’ disease.
Methods and materials: Patients with Graves’ hyperthyroidism underwent pinhole thyroid imaging, 24-h radioactive
iodine uptake (RAIU) measurements and clinical examination and received a calculated 131I activity of 0.2 mCi per
estimated gram of thyroid tissue, adjusted for the 24-h RAIU. The goal of RAI treatment was to achieve hypothyroidism
within 3–6months of 131I administration. Response to RAI therapy was assessed at 7 weeks and 3months by clinical
and biochemical follow-up.
Results: The study included 316 hyperthyroid patients with Graves’ disease (F238:M78, mean age 42.1 ± 16 y, 4–94).
179 patients (56.6%) had no prior therapeutic intervention (treatment-naive patients), whereas 6 patients had prior
thyroid surgery, and 131 (41.5%) had been treated with anti-thyroid medications.
The mean estimated thyroid gland size was 50.2 g ± 18, range 15–100. Mean RAIU was 0.57 ± 0.17 (normal 0.07–0.30).
RAI doses ranged from 5 to 70mCi (mean dose = 18.1 mCi). Successful treatment of hyperthyroidism at our institution
was obtained after a single therapeutic 131-I activity administration in 295 of 316 (93.3%) patients. Multivariate logistic
regression analysis demonstrated that failure of 131I therapy was associated with previous PTU therapy (p < 0.001).
The mean response time after successful RAI therapy was 110.2 days, with cumulative response of 25% at 61 days, 50%
by 84 days and 75% by 118 days after radioiodine administration. The mean time to respond for those on prior PTU
medications was 297 days compared to 116 days for those on MMI and 109 days for those not previously treated with
antithyroid medications. In patients with persistent hyperthyroidism, failure of RAI therapy was documented in 16
patients (76.2%) within (less than) one year after 131I administration and in 5 patients (23.8%) more than one year after
initial therapy, considered late failure.
Conclusion: Successful 131I therapy for Graves’ hyperthyroidism with a single calculated dose can be achieved in the
majority (> 90%) of patients, adjusting for the thyroid size and 24 h uptake measurement.
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Introduction
Hyperthyroidism affects 0.5% of the population in the
USA, with female preponderance (F5–10:M1) peaking be-
tween 40 and 60 years [1]. Radioactive iodine 131I (RAI)
treatment is an effective definitive treatment of hyperthy-
roidism, used as a first line or second line treatment for
over six decades, 131I being selectively concentrated by
functioning thyroid tissue that subsequently is destroyed
over weeks by beta-radiation [1–3]. 131I is a safe and
well-tolerated treatment for hyperthyroidism due to
Graves’ disease, multinodular goiter and autonomously
hyperfunctioning nodule [4].
The goals and methods for delivery of RAI therapy
vary between institutions with many published protocols.
Of note is ongoing debate between use of high doses
versus low doses of 131I [2] and whether the goals of
treatment are immediate hypothyroidism, which is easier
to manage with levothyroxine replacement, rather than
long-term medical management of hyperthyroidism [5].
Some authors have proposed fixed doses of administered
131I, usually between 185 and 550MBq (5–15mCi),
whilst others have adopted dosimetric approaches,
based on calculations that take into account RAIU
measurements and thyroid volume [1], selecting a
dose of RAI therapy to attain a target absorbed dose
to thyroid tissue [2].
Few investigators have evaluated the success rate of
131I therapy in eliminating hyperthyroidism, particularly
with a single dose of radioactivity [6]. Our aim was to
evaluate the success rate of RAI therapy in eliminating
hyperthyroidism (goal of hypothyroidism and levothyr-
oxine replacement), using a single dose of 131I with
dosimetric approach and to determine any factors con-
tributing to failure or prolonged response times.
Methods and materials
Patients
We reviewed clinical records and collected data on
consecutive hyperthyroid patients referred between 1990
and 1998 to the University of Michigan Nuclear
Medicine Therapy Clinic for radioactive iodine (RAI)
thyroid gland ablation procedure for definitive treatment
of hyperthyroidism. This time period of data collection
reflects when the 131I RAI therapy protocol was initially
developed, although the methodology is essentially
unchanged from our contemporary practice. Approval
for retrospective analysis of clinical and laboratory infor-
mation with waiver of consent was obtained from the
Internal Review Board.
Thyrotoxicosis was diagnosed on the basis of elevated
free T4 (FT4) and/or total T3 (TT3) values and TSH
suppressed to < 0.01 mIU/L. Subclinical thyrotoxicosis
was diagnosed as normal FT4 and TT3 values with TSH
suppressed between 0.3 to < 0.01 mIU/L on more than
one occasion over several months of observation. The
etiology of hyperthyroidism due to Graves’ disease was
established by the combination of characteristic clinical
features, laboratory data and results of thyroid imaging.
Graves’ disease was diagnosed based on clinical examin-
ation; diffuse bilateral thyroid gland enlargement without
nodules, either with or without typical findings of
Graves’ eye disease and the presence of thyroid stimulat-
ing immunoglobulin assays (TSIS). When the history
and clinical examination were uncertain, 99mTc-pertech-
netate thyroid pinhole imaging demonstrating a diffuse
increased radiotracer activity throughout the thyroid
gland, without focal nodularity, was considered an
imaging pattern characteristic of Graves’ disease.
Patients on antithyroid medication had it held for at
least 7 days prior to RAI therapy. In preparation for RAI
therapy patients underwent clinical examination,
99mTc-pertechnetate thyroid pinhole imaging, and RAIU
uptake measurements at 24 h. Clinical evaluation in-
cluded neck palpation to estimate thyroid gland size.
Radioactive iodine uptake (RAIU) was measured after an
oral 6–9 μCi dose of 131I with anterior neck counts
measured with a probe placed at 25 cm from the
patient at 24 h post administration; comparison was
made with a daily standard corrected for background
with a lead shield placed in front of the neck of the
patient. 24 h RAIU was variable, but generally ele-
vated (> 30% at 24 h).
We used a therapeutic 131I activity calculated to
deliver a dose of 0.2 mCi per gram of estimated thyroid
tissue at 24 h by the formula:
131l activity mCið Þ dose
¼ 0:2mCi per gram of thyroid tissue x target thyroid tissue mass
RAIU
The desired dose to be retained in the thyroid is one
that delivers 15,000–20,000 rad to the thyroid. This oc-
curs when approximately 150–200 microCi/g is retained
in the gland.
This dose is generally increased when: the gland is
very large, there is evidence for very rapid turnover of
131I (higher 6 h than 24 h uptake, small gland), there has
been prior anti-thyroid drug treatment, there is toxic
nodular disease and when persons are severely toxic and
a rapid response is desired (although a cooling off period
is required).
Clinical follow-up was performed at 7 weeks and 3
months after 131I administration and included review of
clinical symptomatology, physical examination and
relevant laboratory data. Successful RAI therapy for
hyperthyroidism was defined as absence of hyperthyroid
symptoms and/or presence of symptoms of
hypothyroidism; and normal to elevated TSH
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concentrations, subnormal to normal FT4 levels and
TT3 levels, a pattern consistent with onset of
hypothyroidism, but prior to the development of bio-
chemical hypothyroidism (elevated TSH). Thyroid hor-
mone replacement therapy was initiated when laboratory
evidence of hypothyroidism was established. Treatment
failure was defined as post-RAI therapy persistent la-
boratory evidence of hyperthyroidism after discontinu-
ation of thyroid hormone replacement therapy.
Statistical analysis
Continuous ordinal data is presented as mean ± SD.
Failure rates are presented as percentages of the total
within each category. Student t-test was employed to
compare parametric data while Mann-Whitney tests
were used to compare non-parametric data. Frequency
was analyzed with Chi-squared and Fisher’s exact test.
Event analysis was performed using time series data,
with an “event” defined as success after RAI treatment
and the time in days after RAI treatment used to gener-
ate Kaplan-Meier curves for response times observed to
achieve hypothyroidism. Wilcoxon (Breslow) test for
equality of survivor (event) functions and Cox propor-
tion hazards regression were used to assess co-factors to
determine effect on odds ratio of successful ablation.
Statistical analysis was performed in STATA version 11
(Stata Corp, College Station, TX). Significance of
findings was established at p < 0.05.
Results
Over a nine-year interval 316 patients (mean age 42.1 ±
16 y, range 4 to 94) were treated with RAI for hyperthy-
roidism due to Graves’ disease. The group was com-
prised of 238 (75.3%) women and 78 (24.6%) men,
including 20 pediatric patients < 18 years old at diagno-
sis. Patients with hyperthyroidism due to toxic multi- or
uni-nodular goiter were excluded. Review of treatment
history for hyperthyroidism prior to 131I administration
revealed: 179 patients (56.6%) had no prior therapeutic
intervention (treatment-naive patients). The remaining
137 (43.4%) patients had received prior treatment for
hyperthyroidism as follows: medical treatment with
anti-thyroid medications in 131 (41.5%) patients, pro-
pylthiouracil (PTU) in 80 (25.3%) patients, methimazole
(MMI) in 37 (11.7%) patients, both PTU and MMI in 14
(4.4%) patients, and thyroid surgery in 6 (1.9%) patients,
either lobectomy or partial thyroidectomy. In one
patient partial thyroidectomy was performed followed by
PTU therapy for persistent hyperthyroidism, while in a
second patient MMI was given also after ineffective
partial thyroidectomy. Table 1.
The mean time between diagnosis of hyperthyroidism
and referral for RAI therapy was 325.9 days, with 78.2%
of patients referred for RAI treatment within 1 year, and
the longest interval being 18 years. The mean thyroid
gland size was 50.2 g ± 18, range 15–100. The mean 24-h
RAIU was 0.57 ± 0.17 (normal 0.07–0.30). The mean
calculated RAI activity was 18.1 ± 6.8 mCi. The mean
actual dosing factor delivered was 0.21 ± 0.14, matching
the usual intended dosing factor of 0.2 mCi per gram in
our clinical practice.
Hyperthyroidism was successfully treated in all
patients eventually and after confirming hypothyroidism
they were commenced on levothyroxine replacement
(mean dose 109 mcg per day) during follow-up, the
Table 1 Patient demographics
Characteristics Number of
patients (%)
Age 42.1 ± 16 y, 4–94a
Pediatric pts. < 18 y 20 (6.3)
Adult pts. ≥ 18 y 296 (93.7)
Total 316
Gender
Female 238 (75.3)
Male 78 (24.6)
Etiology of hyperthyroidism
Graves’ disease 316 (100%)
History of prior treatment
None 179 (56.6)
Anti-thyroid medications
Propylthiouracil 80 (25.3)
Methimazole 37 (11.7)
Both (PTU and MMI) 14 (4.4)
Total 137 (43.4)
Surgery
Yes 6 (1.9)
Interval between diagnosis and radioiodine
treatment
325.9 d, 0–6818
Radioiodine treatment
Size of gland (g) 50.2 ± 18.1, 15–100a
24-h RAIU 0.57 ± 0.17
131I dose administered (mCi) 18.1 ± 6.8, 5–70a
Dosing factor (mCi per gram) 0.21 ± 0.14
Outcomes at First RAI Therapy 316
Success 295 (93.3)
Failure 21 (6.6)
Failure (needed 2 RAI doses) 18 (5.7)
Failure (needed thyroidectomy) 1 (< 0.3)
Failure (needed 3 RAI doses) 2 (< 0.7)
Interval between radioiodine treatment and
hypothyroidism
97.3 d ± 78.4
apresented as mean ± SD, range
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longest follow-up interval being 2.7 years. No patients
were found to be euthyroid without hormone replace-
ment after RAI therapy. We excluded 7 patients from
analysis of our institutional failure rate, whom had a his-
tory of prior RAI treatment, these patients being treated
at outside institutions by different methods based on
fixed 131I doses without calculations based on goiter size
and RAIU. Six of these 7 patients were successfully
treated by RAI therapy at our center, the last needing
one more RAI dose administration to achieve
hypothyroidism.
The intended goal of achieving hypothyroidism with
RAI treatment using a single dose administration
occurred in 295 of 316 (93.3%) patients. There were
21 patients who failed their first RAI therapy; of these
18 patients subsequently developed hypothyroidism
after receiving a 2nd RAI therapy, 2 patients required
a total of 3 RAI treatments to achieve
hypothyroidism, and 1 underwent thyroidectomy with
subsequent cure of their hyperthyroidism, due to pa-
tient decision after reconsidering their treatment
options.
Among 78 men, 69 (88%) were successfully treated
with a single dose of RAI treatment and 9 had per-
sistent hyperthyroidism. Among 238 women, 226
(95%) were successfully treated and 12 had persistent
hyperthyroidism. The RAI therapy failures in men
were significantly higher than in women (12 vs. 5%,
P = 0.046). Among patients with failed RAI therapy
and persistent hyperthyroidism, 17 patients (80.9%)
were previously treated with antithyroid medications,
MMI, PTU or both, while only 3 patients (14.2%)
were treatment-naive (p < 0.001). By univariate ana-
lysis successful treatment was more likely with
smaller mean thyroid size (49.3 g versus 62.1 g, P =
0.0017) (see Table 2).
Multivariate logistic regression analysis demonstrated
that failure of 131I therapy was associated with previous
PTU therapy (p 0.004) but not with MMI therapy, dose
of 131I therapy, RAIU values before therapy or dose of
131I administered. Gender and size were no longer
significant by multivariate analysis.
In 295 patients with successful ablation after their first
RAI treatment, the mean time to response defined as
development of hypothyroidism and initiation of
levothyroxine replacement was 97.3 days ±78.4 range 1
to 733 days. Using event analysis of the successful 131I
treatment (where an event was defined as time to suc-
cessful treatment), Kaplan-Meier analysis of all treated
patients demonstrated an exponential function and the
mean response time after successful RAI ablation was
110.2 days, with cumulative response rate of 25% at 61
days, 50% by 84 days and 75% by 118 days (Fig. 1). The
mean time to respond for those on prior PTU
medications was 297 days compared to 116 days for
those on MMI and 109 days for those not previously
treated with antithyroid medications (Fig. 2). Regarding
early versus late responders, there were approximately
91% responding by 200 days post RAI (~ 6months) with
~ 9% late-responders (> 6 months). This represented the
greatest hazard ratio for success occurred at 100 days
(Fig. 3). In 21 patients with persistent hyperthyroidism,
failure of RAI therapy was documented in 16 patients
(76.2%) within (less than) one year after 131I administra-
tion and in 5 patients (23.8%) more than one year after
initial therapy, considered late failure.
Discussion
Many endocrinologists prefer an ablative dose of radio-
active iodine to treat Graves’ hyperthyroidism. Doses of
131I in the range of 0.15–0.2 mCi per gram of thyroid
tissue produce quicker resolution of hyperthyroidism
than smaller dose therapies, lessening morbidity related
to hyperthyroidism [7]. Although, higher doses of 131I
are associated with higher success rates of RAI therapy
this must be balanced with the need to avoid unneces-
sary absorbed radiation dose to the patients, family
members and members of the general public, in accord-
ance with the As Low As Reasonably Achievable
(ALARA) principle. Conversely, treatment failures are
associated with additional RAI treatments and dose
exposure. American Thyroid Association (ATA) guide-
lines endorse the goal of hypothyroidism which can
be achieved with simple fixed versus dosimetric ap-
proaches, although there is a recommendation for cal-
culated doses > 150 microCi per gram of thyroid
tissue [1].
We adopted goals of ending hyperthyroidism within 3–
6months to limit disability and to reduce the costs of
multiple therapies. Our treatment goal is hypothyroidism,
which is easier to manage with levothyroxine replacement,
rather than long-term medical management of hyperthy-
roidism [5]. This is due to the inability to calculate dose
with the aim to achieve euthyroidism, the progression to
hypothyroidism even after a period of euthyroidism and
the higher risk of recurrent hyperthyroidism which may
occur if hypothyroidism is not achieved [5, 8]. By using
prescriptions of 0.2 mCi per gram of thyroid tissue calcu-
lated from clinical estimates of thyroid volume, and 131I
uptake at 1 day, we show that persistence of hyperthyroid-
ism was 7% overall and that these failures were largely
associated with prior propylthiouracil (PTU) therapy. No
significant differences were found in outcomes related to
RAIU or dose of radioactivity. By univariate analysis age,
size and gender were significant factors influencing suc-
cess rate of RAI therapy, however by multivariate analysis
these factors became non-significant, possibly due to older
patients receiving antithyroid medications. Furthermore, it
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is very likely that the patients with increased time interval
were managed on anti-thyroid medications, and during
this time the goiter enlarged.
In a nine year prospective study of 131I versus anti-
thyroid medications, Chen and co-workers treated
209 patients with RAI therapy (178 single, 26 twice
and 5 three times), using calculated doses ranging be-
tween 185–444MBq [6]. Patients were not pretreated
with antithyroid medications. Radioiodine was safe
with no cases of thyroid storm or leukemia observed.
Those treated twice or three times needed 263 ± 123
MBq. There was a 100% cumulative permanent
hypothyroid rate at 100 months, with just over 24.4%
conversions to hypothyroidism at 6 months and 62.2%
achieved by 2 years. Of note similar to our findings
higher gland weight was associated with longer time
to cure (P = 0.001). The authors concluded that
low-dose radioiodine has better cure rates than
Fig. 1 Kaplan-Meier response curve for successful RAI therapy
Table 2 Co-factors between cohorts of success and failure of first RAI therapy for hyperthyroidism
Variable Success
(n = 295)
Failure
(n = 21)
P value
Age (y) at time of diagnosis 41.9 45.5 NS (P = 0.32)
Gender (F:M) 226:69 12:9 (P = 0.046)
No prior treatment 176 (59.7%) 3 (14.2%) (P < 0.001)
Prior antithyroid medication 114 (38.6%) 17 (80.9%) (P < 0.001)
Methimazole n = 35 n = 2 (P < 0.001)
Propylthiouracil n = 79 n = 15 (P < 0.001)
Interval from diagnosis to treatment (d) 329.6 289.6 (P = 0.024)
Size of thyroid gland (grams) 49.3 62.1 (P = 0.0017)
24-h RAIU uptake 0.56 0.62 NS (P = 0.235)
Dose of RAI 131I administered (mCi) 18.1 19.9 NS (P = 0.193)
Dosing factor (mCi per gram) 0.21 0.19 NS (P = 0.259)
Weight (lbs) 150.1 136.8 NS (P = 0.050)
Thyrotropin (TSH)
(normal 0.3–5.5 mIU/L)
0.13 0.010 NS (P = 0.948)
Total tri-iodothyronine (TT3)
(normal 95–170 pg/mL)
328 415 NS (P = 0.139)
Free thyroxine (FT4)
(normal 0.73–1.79 ng/dL)
3.2 3.8 (P = 0.026)
Race: caucasian 212 (71.8%) 11 (52.5%) NS (P = 0.195)
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antithyroid medications, and lower relapse rates, at the
expense of higher percentages of hypothyroid patients.
In one randomized trial of fixed versus calculated
doses it was reported that fixed doses had success rate
of 71% versus calculated doses of only 58%, however the
success rate of fixed doses decreased with higher thyroid
volumes (> 75 g) to only 25%. Whereas, in these large
thyroid glands the calculated doses had 45% success rate
[2]. Traino and colleagues looked at 3 different calcu-
lated doses with 400 Gray (Gy) delivered to the thyroid
gland having the highest cure rate of 97% [9]. In a study of
84 patients treated with RAI therapy followed at 4–5
months, 14 were euthyroid, 49 hypothyroid and 21 hyper-
thyroid. No single factor predicted early hypothyroidism
in this study [10]. In a study of 72 patients treated with
calculated dose a significant difference in outcomes
between low versus high-dose was noted [11]. A
meta-analysis was inconclusive for superior outcomes or
efficacy between fixed versus calculated doses [12].
The outcomes of 119 Graves’ disease patients were re-
ported treated with a dosimetric protocol between 2003
and 2008, along with simulations of other protocols,
followed for 12 months after treatment. A group receiv-
ing 120–200 Gray (Gy) radiation dose to the thyroid was
prescribed, leading to a cure of hyperthyroidism with a
single radioiodine administration in 53% of patients.
When a higher radiation dose to the target (200–250
Gy) was prescribed this outcome raised up to 89%
Fig. 2 Kaplan-Meier response curve for successful RAI therapy by prior treatment history
Fig. 3 Hazard curve for successful RAI therapy
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although the administered activities were still lower, as a
rule, than the most commonly employed fixed activities
(400–600MBq). The authors found that there existed a
high level of individual dose optimization, particularly
when compared to simplified methods [13]. In a study
of 59 patients the dosimetric method was used for
diffuse goiter and nodular goiter. The protocols,
which have not taken into account the thyroid mass,
multi pre-therapeutic 131I uptakes and the effective
half-life of 131I of the individual patient, showed a
higher degree of deviation from the required thyroid dose.
According to the results for diffuse goiter and nodular goi-
ter, respectively, 28 and 54% patients were under-dosed
and 72 and 46% patients were over-dosed [14].
A study of patients randomized into two treatment
groups, one receiving 60 Gy and the other receiving
90 Gy thyroid tissue absorbed dose of radioiodine. At
6 months, five patients in the 90 Gy group were
hypothyroid, compared to two patients in the 60 Gy
group (P = 0.246). Overall at 6 months,
non-responders to low-dose therapy had a signifi-
cantly larger thyroid gland mass (respective means:
35.9 ml vs 21.9 ml). Where low-dose radioiodine
treatment of Graves’ disease is considered, a dose of
60 Gy will yield a 39% response rate at 6 months
while minimizing early hypothyroidism. No signifi-
cant advantage in response rate is gained by using a
dose of 90 Gy [15].
The use of antithyroid medications and the effect on
RAI therapy remains controversial, although with a
number of different protocols were tested taking into ac-
count history of prior antithyroid medication use [16].
We found that PTU, but not MMI to be associated with
delayed response time. There is a suggestion that PTU
may cause increased resistance of thyroid tissue to radi-
ation effect and subsequent successful response rates
[17–19]. Others have not reported this to be an issue
with MMI or carbimazole [20, 21]. In a meta-analysis of
14 RCTs with 1269 patients [7], the risk of antithyroid
medications on unsuccessful RAI therapy was 1.28, CI
1.07–1.52 (p = 0.004) compared to no antithyroid medi-
cations. There included MMI (6 trials), PTU (4 trials),
carbimazole (3 trials) and one comparing PTU with
MMI. The effect on achieving hypothyroidism was inde-
pendent of antithyroid drug choice [7].
One of the limitations of our study was that we were
unable to report on the adverse effects attributable to
the 131I administration as this data was not consistently
recorded in the medical record. Our data collection was
from the time period when the protocol for the calcula-
tion of 131I doses was initially developed. However, we
consider the results of this study applicable to our con-
temporary practice, as the protocol is largely unchanged
from when it was initially developed. The only change
has been the introduction of a 1 week low-iodine diet
preparation around 3 years ago which could affect the
uptake measurements though not the efficacy of 131I
administration. Another limitation of this study are we
were unable to evaluate the impact of TSIS on treatment
failure. Finally, the mean time to response was calculated
based on follow-up result of hypothyroidism which may
have underestimated the true time to hypothyroidism.
However, since patients called with symptoms of
hypothyroidism and were brought in the discrepancy in
our measured time to response and actual development
of hypothyroidism was minimal.
Conclusion
Using calculations of dose of RAI based upon thyroid
gland size and correcting for radioiodine uptake, success-
ful treatment with a single dose of RAI can be achieved
with a 7% first therapy failure rate, with few patients
requiring additional doses of RAI.
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